Immunotherapy Withdrawals Put Spotlight on Accelerated Approval

Elie Dolgin • June 1, 2021

The FDA's Accelerated Approval program is under scrutiny after four drug companies announced plans in recent months to withdraw indications for checkpoint inhibitors that, despite showing early promise, failed to demonstrate a survival benefit in confirmatory trials. The agency's Oncologic Drugs Advisory Committee will meet in late April to discuss whether six more indications for some of these same immunotherapies should be nullified as well.

Continue reading at Cancer Discovery.

Blue and gold fibrous texture in the shape of brain
By Elie Dolgin June 30, 2025
AI and real-time neural feedback could transform treatments.
Damaged 15th century painting by the Master of the Prado Adoration of the Magi
By Elie Dolgin June 12, 2025
Pixels meet paint, as a digital “mask” conceals damage on a 15th-century painting.